Overview

Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia

Status:
Completed

Trial end date:
2007-12-01

Target enrollment:

Participant gender:

Summary

To compare the complete cytogenetic response rate in patients with newly-diagnosed chronic-phase chronic myeloid leukaemia treated with Glivec® alone or in combination with interferon at low doses

Phase:

Phase 4

Details

Lead Sponsor:

PETHEMA Foundation

Treatments:

Imatinib Mesylate
Interferon-alpha
Interferons